AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed diagnosis of 1 of the following:
• * Non-small cell lung cancer (NSCLC) (closed to accrual as of 8/9/07) meeting 1 of the following stage criteria:
• * Stage IIIB disease
• * Patients without pleural effusion who are not candidates for combined modality treatment OR who were treated at centers where combined modality treatment is not considered standard treatment are eligible
• * Stage IV disease
• * Local or metastatic failure after prior surgery and/or radiotherapy
• * Colorectal cancer
• * Metastatic disease
• * Considered suitable for first-line therapy with capecitabine
• * Other tumor types
• * Suitable for treatment with capecitabine
• * No more than 2 prior chemotherapy regimens for advanced or metastatic disease
• Incurable by radiotherapy or surgery
• Clinically or radiologically documented disease
• * No tumor marker elevation as the only evidence of disease
• No necrotic or hemorrhagic tumor or metastases
• No untreated brain or meningeal metastases
• * Patients with previously treated stable brain metastases (by radiography or clinical exam) are eligible provided they are asymptomatic and do not require corticosteroids
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• At least 12 weeks (colorectal cancer patients)
• Hematopoietic
• Hemoglobin adequate
• * Anemia allowed provided patient is well compensated with no evidence of recent bleeding
• Absolute granulocyte count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• No overt bleeding (i.e., ≥ 30 mL/episode) within the past 3 months
• Hepatic
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT or AST ≤ 2 times ULN (5 times ULN for documented liver metastases)
• Renal
• Creatinine ≤ 1.5 times ULN OR
• Creatinine clearance ≥ 50 mL/min
• No proteinuria \> grade 1
• Cardiovascular
• Resting systolic blood pressure ≤ 150 mm Hg AND/OR resting diastolic blood pressure ≤ 100 mm Hg (in the presence or absence of a stable dose of antihypertensive medication)
• Mean QTc ≤ 470 msec (with Bazetts correction) by ECG
• LVEF \> 50% for patients with prior anthracyclines/trastuzumab or cardio-toxic agents
• No untreated or uncontrolled cardiovascular condition
• No symptomatic cardiac dysfunction
• No poorly controlled hypertension
• No history of labile hypertension
• No history of poor compliance with antihypertensive medication
• No history of familial long QT syndrome
• Pulmonary
• No clinically relevant hemoptysis (i.e., ≥ 5 mL fresh blood) within the past 4 weeks
• * Patients with only flecks of blood in their sputum are eligible
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective (double-method for females; barrier method for males) contraception
• No prior allergic reaction to drugs containing Cremophor EL® (NSCLC patients \[closed to accrual as of 8/9/07\])
• No peripheral neuropathy \> grade 1 (NSCLC patients \[closed to accrual as of 8/9/07\])
• No dihydropyrimidine dehydrogenase deficiency (colorectal cancer patients)
• No history of severe hand-foot syndrome after treatment with fluoropyrimidines (colorectal cancer patients)
• No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or other curatively treated solid tumor
• No active or uncontrolled infection
• No other serious illness or medical condition that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior antiangiogenesis therapy
• Chemotherapy
• At least 4 weeks since prior single-agent non-platinum-containing chemotherapy (6 weeks for nitrosoureas or mitomycin) for metastatic disease (NSCLC patients \[closed to accrual as of 8/9/07\])
• * No more than 1 prior single-agent non-platinum-containing chemotherapy regimen for metastatic disease
• At least 6 months since prior adjuvant or neoadjuvant chemotherapy
• No prior taxane therapy (NSCLC patients \[closed to accrual as of 8/9/07\])
• No prior chemotherapy for metastatic disease (colorectal cancer patients)
• No prior capecitabine (colorectal cancer patients)
• Endocrine therapy
• See Disease Characteristics
• At least 4 weeks since prior corticosteroids
• Radiotherapy
• See Disease Characteristics
• At least 21 days since prior palliative radiotherapy except for low-dose non-myelosuppressive radiotherapy with approval
• At least 6 months since prior adjuvant radiotherapy
• Surgery
• See Disease Characteristics
• At least 14 days since prior major surgery
• Other
• Recovered from prior therapy
• At least 14 days since prior epidermal growth factor receptor inhibitor therapy
• Concurrent oral anticoagulants (e.g., warfarin) allowed provided INR is strictly monitored
• No other concurrent investigational therapy
• No other concurrent anticancer therapy
• No concurrent prophylactic pyridoxine (vitamin B\_6) for hand-foot syndrome (colorectal or other tumor type patients)
• * Use of pyridoxine after the onset of hand-foot syndrome allowed at the discretion of the physician